Enfusion, Inc. (NYSE:ENFN) Sees Large Increase in Short Interest

Enfusion, Inc. (NYSE:ENFN - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 1,300,000 shares, an increase of 28.7% from the March 15th total of 1,010,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the short-interest ratio is currently 1.1 days. Currently, 3.3% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th.

Enfusion Trading Up 0.5 %

Shares of NYSE:ENFN traded up $0.05 during midday trading on Wednesday, hitting $10.85. The company had a trading volume of 2,461,878 shares, compared to its average volume of 635,546. Enfusion has a 12 month low of $7.83 and a 12 month high of $11.80. The firm has a fifty day simple moving average of $11.07 and a 200 day simple moving average of $10.45. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 271.29, a PEG ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The company had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. Equities analysts forecast that Enfusion will post 0.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Oleg Movchan sold 2,790 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $32,029.20. Following the completion of the sale, the chief executive officer now owns 643,299 shares in the company, valued at $7,385,072.52. The trade was a 0.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Neal Pawar sold 2,769 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total value of $31,788.12. Following the transaction, the chief operating officer now directly owns 1,231,627 shares in the company, valued at $14,139,077.96. This trade represents a 0.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,223 shares of company stock valued at $754,778 in the last 90 days. 36.44% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enfusion

Hedge funds have recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in shares of Enfusion in the 4th quarter valued at $75,000. FNY Investment Advisers LLC acquired a new stake in Enfusion during the 1st quarter worth approximately $111,000. Millennium Management LLC bought a new position in Enfusion in the fourth quarter valued at approximately $114,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Enfusion by 30.2% in the first quarter. Harbor Capital Advisors Inc. now owns 10,201 shares of the company's stock valued at $114,000 after buying an additional 2,366 shares during the period. Finally, Dark Forest Capital Management LP bought a new stake in shares of Enfusion during the fourth quarter worth $128,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.